Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SW-H-201 + sintilimab
- Development stage
- Unknown
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
The combination of a personalized neoantigen mRNA vaccine (SW-H-201) and sintilimab is an investigational immunotherapy regimen being evaluated for the adjuvant treatment of hepatocellular carcinoma (HCC). The vaccine component is custom-designed for each patient, encoding unique neoantigens identified through genomic sequencing of the individual's tumor to trigger a specific T-cell response. Sintilimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to prevent the tumor from suppressing the immune system. By combining these two agents, the therapy aims to both prime the immune system against specific tumor targets and sustain that immune activity by blocking inhibitory signals, thereby reducing the risk of postoperative recurrence in HCC patients.
- Other names
- Neoantigen mRNA Personalised Cancer vaccine + SintilimabmRNA Personalized Tumor Vaccine + SintilimabNeoantigen mRNA Personalised Cancer vaccine + Stintilimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on SW-H-201 + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SW-H-201 + sintilimab.